Quality ManagementAnthem Blue Cross and Blue Shield | Medicare AdvantageAMH Health, LLC | Medicare AdvantageMarch 31, 2025

Kidney Health Evaluation for Patients With Diabetes (KED) 2025

HEDIS® is a widely used set of performance measures developed and maintained by NCQA. These are used to drive improvement efforts surrounding best practices.

HEDIS measure

This measure evaluates patients 18 to 85 years of age with diabetes (type 1 and type 2) who received a kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR), and a urine albumin-creatinine ratio (uACR) during the measurement year.

Refer to attachments to view full details

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).

Anthem Blue Cross and Blue Shield is the trade name of Anthem Health Plans of Maine, Inc. Independent licensee of the Blue Cross Blue Shield Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

Plans offered by AMH Health, LLC., a joint venture between MaineHealth and Anthem Partnership Holding Company, LLC. AMH Health is an independent licensee of the Blue Cross Blue Shield Association.

MULTI-BCBS-CR-075750-24-CPN74992, MEAMH-CR-075745-24-CPN74992, MEAMH-CR-080029-25-CPN79905, MULTI-BCBS-CR-080034-25-CPN79905

ATTACHMENTS: Kidney Health Evaluation for Patients With Diabetes (KED) 2025 - AMH Health, LLC (pdf - 0mb), Kidney Health Evaluation for Patients With Diabetes (KED) 2025 - Blue Cross Blue Shield (pdf - 0mb)